KALARIS THERAPEUTICS, INC. Increase (Decrease) in Other Noncurrent Assets
KALARIS THERAPEUTICS, INC. (KLRS) reported Increase (Decrease) in Other Noncurrent Assets of $796.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherNoncurrentAssets · last filed 2026-08-11
- KALARIS THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2026-06-30 was -$14.00K.
- KALARIS THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2026-03-31 was $810.00K.
- KALARIS THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2025-12-31 was -$15.00K, a 115.63% decline year-over-year.
- KALARIS THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for the quarter ending 2025-09-30 was $89.00K, a 79.59% decline year-over-year.
- KALARIS THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for fiscal 2025 was $355.00K, a 13.41% decline from fiscal 2024.
- KALARIS THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for fiscal 2024 was $410.00K, a 54.44% decline from fiscal 2023.
- KALARIS THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for fiscal 2023 was $900.00K.
- KALARIS THERAPEUTICS, INC. increase (decrease) in other noncurrent assets for fiscal 2022 was -$490.00K, a 144.46% decline from fiscal 2021.
| Period end | Increase (Decrease) in Other Noncurrent Assets 3 month | Increase (Decrease) in Other Noncurrent Assets 6 month | Increase (Decrease) in Other Noncurrent Assets 9 month | Increase (Decrease) in Other Noncurrent Assets 9 month as first filed | Increase (Decrease) in Other Noncurrent Assets 12 month | Increase (Decrease) in Other Noncurrent Assets 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $796.00K 10-Q · filed 2026-08-11 | $781.00K derived: sum of 3 quarters · filed 2026-08-11 | $870.00K derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $810.00K 10-Q · filed 2026-05-12 | $795.00K derived: sum of 2 quarters · filed 2026-05-12 | $884.00K derived: sum of 3 quarters · filed 2026-05-12 | |||
| 2025-12-31 | -$15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $74.00K derived: sum of 2 quarters · filed 2026-03-17 | $355.00K 10-K · filed 2026-03-17 | |||
| 2025-09-30 | $89.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $370.00K 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | $281.00K 10-Q · filed 2026-08-11 | |||||
| 2024-12-31 | $96.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $532.00K derived: sum of 2 quarters · filed 2026-03-17 | $532.00K derived: sum of 3 quarters · filed 2026-03-17 | $410.00K 10-K · filed 2026-03-17 | -$122.00K 10-K · filed 2025-03-07 | |
| 2024-09-30 | $436.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $436.00K derived: sum of 2 quarters · filed 2025-11-12 | $314.00K 10-Q · filed 2025-11-12 | -$122.00K 10-Q · filed 2024-11-12 | $401.00K derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$122.00K 10-Q · filed 2024-08-09 | -$35.00K derived: sum of 3 quarters · filed 2025-03-07 | $706.00K derived: sum of 4 quarters · filed 2025-03-07 | ||
| 2024-03-31 | -$122.00K 10-Q · filed 2024-05-13 | -$35.00K derived: sum of 2 quarters · filed 2025-03-07 | $706.00K derived: sum of 3 quarters · filed 2025-03-07 | $900.00K derived: sum of 4 quarters · filed 2025-03-07 | ||
| 2023-12-31 | $87.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $828.00K derived: sum of 2 quarters · filed 2025-03-07 | $1.02M derived: sum of 3 quarters · filed 2025-03-07 | $900.00K 10-K · filed 2025-03-07 | ||
| 2023-09-30 | $741.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $935.00K derived: sum of 2 quarters · filed 2024-11-12 | $813.00K 10-Q · filed 2024-11-12 | $690.00K derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $194.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $72.00K 10-Q · filed 2024-08-09 | -$51.00K derived: sum of 3 quarters · filed 2024-08-09 | -$173.00K derived: sum of 4 quarters · filed 2024-08-09 | ||
| 2023-03-31 | -$122.00K 10-Q · filed 2024-05-13 | -$245.00K derived: sum of 2 quarters · filed 2024-05-13 | -$367.00K derived: sum of 3 quarters · filed 2024-05-13 | -$490.00K derived: sum of 4 quarters · filed 2024-05-13 | ||
| 2022-12-31 | -$123.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$245.00K derived: sum of 2 quarters · filed 2024-03-15 | -$368.00K derived: sum of 3 quarters · filed 2024-03-15 | -$490.00K 10-K · filed 2024-03-15 | ||
| 2022-09-30 | -$122.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$245.00K derived: sum of 2 quarters · filed 2023-11-02 | -$367.00K 10-Q · filed 2023-11-02 | -$471.00K derived: sum of 4 quarters · filed 2023-11-02 | ||
| 2022-06-30 | -$123.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$245.00K 10-Q · filed 2023-08-03 | -$349.00K derived: sum of 3 quarters · filed 2023-08-03 | $165.00K derived: sum of 4 quarters · filed 2023-08-03 | ||
| 2022-03-31 | -$122.00K 10-Q · filed 2023-05-04 | -$226.00K derived: sum of 2 quarters · filed 2023-05-04 | $288.00K derived: sum of 3 quarters · filed 2023-05-04 | |||
| 2021-12-31 | -$104.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $410.00K derived: sum of 2 quarters · filed 2023-02-15 | $1.10M 10-K · filed 2023-02-15 | |||
| 2021-09-30 | $514.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.21M 10-Q · filed 2022-11-03 | ||||
| 2021-06-30 | $692.00K 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |